GDTC
Income statement / Annual
Last year (2025), CytoMed Therapeutics Ltd's total revenue was $324.39 K,
an increase of 366.74% from the previous year.
In 2025, CytoMed Therapeutics Ltd's net income was -$3.98 M.
See CytoMed Therapeutics Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$324.39 K |
$69.50 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$67.99 K
|
$17.12 K
|
$4.36 M
|
$0.00
|
$3.50 K
|
$4.63 K
|
$0.00
|
| Gross Profit |
$256.40 K
|
$52.38 K
|
-$4.36 M
|
$0.00
|
$110.29 K
|
$54.84 K
|
$0.00
|
| Gross Profit Ratio |
0.79
|
0.75
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$2.22 M
|
$1.91 M
|
$0.00
|
$1.52 M
|
$1.09 M
|
$1.04 M
|
$439.80 K
|
| General & Administrative Expenses |
$2.60 M
|
$1.62 M
|
$0.00
|
$705.33 K
|
$585.98 K
|
$148.68 K
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.48 K
|
$6.18 K
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.60 M
|
$1.62 M
|
$0.00
|
$705.33 K
|
$588.46 K
|
$154.86 K
|
$40.35 K
|
| Other Expenses |
$226.80 K
|
$122.40 K
|
$0.00
|
$111.75 K
|
-$411.78 K
|
-$12.61 K
|
$171.74 K
|
| Operating Expenses |
$5.05 M
|
$3.65 M
|
$0.00
|
$2.34 M
|
$1.27 M
|
$1.18 M
|
$651.88 K
|
| Cost And Expenses |
$5.11 M
|
$3.67 M
|
$4.36 M
|
$2.34 M
|
$1.89 M
|
$1.33 M
|
$651.88 K
|
| Interest Income |
$123.90 K
|
$317.67 K
|
$285.72 K
|
$2.10 K
|
$3.39 K
|
$105.51 K
|
$27.23 K
|
| Interest Expense |
$20.91 K
|
$20.31 K
|
$51.28 K
|
$125.18 K
|
$118.39 K
|
$105.51 K
|
$0.00
|
| Depreciation & Amortization |
$401.58 K
|
$335.36 K
|
$381.15 K
|
$392.87 K
|
$329.88 K
|
$292.53 K
|
$177.52 K
|
| EBITDA |
-$3.57 M |
-$2.17 M |
-$3.70 M |
-$2.61 M |
-$1.56 M |
-$1.04 M |
-$429.06 K |
| EBITDA Ratio |
-11.02
|
-31.17
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-14.76
|
-51.75
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$792.74 K
|
$1.08 M
|
$228.51 K
|
-$789.97 K
|
-$900.44 K
|
-$529.63 K
|
-$206.87 K
|
| Income Before Tax |
-$4.00 M
|
-$2.52 M
|
-$4.13 M
|
-$3.13 M
|
-$2.06 M
|
-$1.86 M
|
-$858.75 K
|
| Income Before Tax Ratio |
-12.32
|
-36.29
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$653.00
|
$1.64 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$3.98 M
|
-$2.52 M
|
-$4.13 M
|
-$3.13 M
|
-$2.07 M
|
-$1.94 M
|
-$858.75 K
|
| Net Income Ratio |
-12.27
|
-36.21
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.34 |
-0.22 |
-0.39 |
-0.4 |
-0.3 |
-0.33 |
-0.15 |
| EPS Diluted |
-0.34 |
-0.22 |
-0.39 |
-0.4 |
-0.3 |
-0.33 |
-0.15 |
| Weighted Average Shares Out |
$11.65 M
|
$11.54 M
|
$10.63 M
|
$7.92 M
|
$6.93 M
|
$5.90 M
|
$5.55 M
|
| Weighted Average Shares Out Diluted |
$11.65 M
|
$11.54 M
|
$10.63 M
|
$7.92 M
|
$6.93 M
|
$5.90 M
|
$5.55 M
|
| Link |
|
|
|
|
|
|
|